Ferreira Izabella C C, Aguiar Emília M G, Silva Alinne T F, Santos Letícia L D, Cardoso-Sousa Léia, Araújo Thaise G, Santos Donizeti W, Goulart Luiz R, Sabino-Silva Robinson, Maia Yara C P
Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlandia, Uberlandia 38405-302, Brazil.
Department of Physiology, Institute of Biomedical Sciences, Federal University of Uberlandia, Uberlandia 38405-302, Brazil.
J Oncol. 2020 Feb 10;2020:4343590. doi: 10.1155/2020/4343590. eCollection 2020.
Saliva biomarkers using reagent-free biophotonic technology have not been investigated as a strategy for early detection of breast cancer (BC). The attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy has been proposed as a promising tool for disease diagnosis. However, its utilization in cancer is still incipient, and currently saliva has not been used for BC screening. We have applied ATR-FTIR onto saliva from patients with breast cancer, benign breast disease, and healthy matched controls to investigate its potential use in BC diagnosis. Several salivary vibrational modes have been identified in original and second-derivative spectra. The absorbance levels at wavenumber 1041 cm were significantly higher ( < 0.05) in saliva of breast cancer patients compared with those of benign patients, and the ROC curve analysis of this peak showed a reasonable accuracy to discriminate breast cancer from benign and control patients. The 1433-1302.9 cm band area was significantly higher ( < 0.05) in saliva of breast cancer patients than in control and benign patients. This salivary ATR-FTIR spectral area was prevalidated as a potential diagnostic biomarker of BC. This spectral biomarker was able to discriminate human BC from controls with sensitivity and specificity of 90% and 80%, respectively. Besides, it was able to differentiate BC from benign disease with sensitivity and specificity of 90% and 70%, respectively. Briefly, for the first time, saliva analysis by ATR-FTIR spectroscopy has demonstrated the potential use of salivary spectral biomarkers (1041 cm and 1433-1302.9 cm) as a novel alternative for noninvasive BC diagnosis, which could be used for screening purposes.
尚未研究使用无试剂生物光子技术的唾液生物标志物作为早期检测乳腺癌（BC）的策略。衰减全反射傅里叶变换红外（ATR-FTIR）光谱已被提议作为一种有前景的疾病诊断工具。然而，其在癌症中的应用仍处于初期阶段，目前唾液尚未用于乳腺癌筛查。我们将ATR-FTIR应用于乳腺癌患者、乳腺良性疾病患者和健康对照者的唾液，以研究其在乳腺癌诊断中的潜在用途。在原始光谱和二阶导数光谱中已识别出几种唾液振动模式。与良性疾病患者相比，乳腺癌患者唾液在波数1041 cm处的吸光度水平显著更高（P<0.05），该峰的ROC曲线分析显示在区分乳腺癌与良性疾病患者及对照者方面具有合理的准确性。乳腺癌患者唾液中1433 - 1302.9 cm波段面积显著高于对照者和良性疾病患者（P<0.05）。该唾液ATR-FTIR光谱区域已被预先验证为乳腺癌的潜在诊断生物标志物。这种光谱生物标志物能够以90%的灵敏度和80%的特异性区分人类乳腺癌与对照者。此外，它能够以90%的灵敏度和70%的特异性区分乳腺癌与良性疾病。简而言之，首次通过ATR-FTIR光谱对唾液进行分析已证明唾液光谱生物标志物（1041 cm和1433 - 1302.9 cm）作为无创乳腺癌诊断新方法的潜在用途，可用于筛查目的。
